[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fat-free-mass\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fat-free-mass":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608067","bio-electrical-impedance-analysis-in-patients-with-functional-dyspepsia-100608067",false,"NCT07196735","Bio-electrical Impedance Analysis in Patients With Functional Dyspepsia","Inclusion Criteria:\n\n* Women aged 18 - 75 years\n* Fulfilling the ROME IV criteria for functional dyspepsia (for FD patients)\n* FD unexplained by upper GI endoscopy during the past 12 months (mild gastritis allowed) (for FD patients).\n\nExclusion Criteria:\n\n* Clinical suspicion of an organic disorder different from FD (patients can be included when this disorder had been excluded);\n* Abnormality on upper GI endoscopy other than mild gastritis (for FD patients).\n* Known reflux oesophagitis Los Angeles grade C or D, known Barrett oesophagus, peptic stricture.\n* H pylori infection, unless treated at least 6 months before;\n* Known inflammatory bowel disorder;\n* Known major intestinal motility disorder;\n* Alcohol (defined as more than 14 U per week) or other substance abuse;\n* Active psychiatric disorder;\n* Known systemic or auto-immune disorder with implication for the GI system;\n* Prior abdominal surgery (with the exception of cholecystectomy or ap-pendectomy);\n* Any prior diagnosis of cancer other than basocellular carcinoma;\n* Current chemotherapy;\n* History of gastro-enteritis in the past 12 weeks;\n* Dietary supplements unless taken at a stable dose for more than 12 weeks;\n* Treatment with neuromodulators (one neuromodulator taken at a sta-ble dose for more than 12 weeks is allowed);\n* Treatment with PPI's during the past 8 weeks\n* Pregnancy.",true,"FEMALE","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to compare the BIA parameters, including Phase Angle, Fat Free Mass and Fat Mass, between women with functional dyspepsia and healthy women. All woman will undergo a bio-electrical impedance monitoring for this.",[25,26,27,28,29],"Functional Dyspepsia","BIA","Fat Free Mass","Fat Mass","Phase Angle","RECRUITING","2025-09-29",{"date":33,"type":34},"2025-10-03","ACTUAL",{"date":36,"type":34},"2025-09-18",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"Universitair Ziekenhuis Brussel","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100604979","protein-supplementation-and-resistance-training-to-prevent-fat-free-mass-loss-following-metabolic-bariatric-surgery-100604979","NCT07156552","Protein Supplementation and Resistance Training to Prevent Fat-Free Mass Loss Following Metabolic-Bariatric Surgery","Effectiveness of Protein SupplementatIon Combined With Resistance Exercise Training to Counteract Disproportional Fat-Free Mass Loss Following Metabolic-Bariatric Surgery: The ENRICHED Study","ENRICHED","Inclusion Criteria:\n\n* A scheduled metabolic-bariatric surgery (i.e. RYGB or Sleeve Gastrectomy)\n* Participation in the NOK care program\n* Able to understand and perform the study procedures\n\nExclusion Criteria:\n\n* Allergic or sensitive for milk proteins, or lactose intolerant\n* Diagnosed renal insufficiency\n* Diagnosed intestinal diseases influencing the uptake of protein (i.e. active inflammatory bowel disease","ALL",{"count":53,"type":21},400,"INTERVENTIONAL",[56],"NA","The goal of this clinical trial is to investigate the effects of daily protein supplementation and participation in a weekly supervised resistance training program on the prevention of excessive muscle mass loss following bariatric surgery. Patients treated at one of the participating centers will be invited to participate and will be randomly assigned to one of two groups.\n\nParticipants in group 1 will receive standard postoperative care as currently provided. Participants in group 2 will also receive standard care, but in addition, they will be asked to consume extra protein daily and take part in a supervised resistance training session once a week.\n\nPrevious research has shown that approximately one in five patients undergoing bariatric surgery experiences excessive muscle loss after the surgery. It is known that resistance training and protein intake can help maintain and even improve muscle mass. However, limited research has been conducted on the combined effects of protein supplementation and resistance training in patients after bariatric surgery. Therefore, the aim of this trial is to determine whether participants receiving the additional intervention experience less muscle mass loss compared to those receiving standard care alone.",[59,27],"Bariatric Surgery",[61,59,62,63,64,65],"Metabolic-Bariatric Surgery","Sleeve Gastrectomy","Roux-en Y Gastric Bypass","Protein Supplementation","Resistance Training","2025-08-27",{"date":68,"type":34},"2025-09-05",{"date":70,"type":34},"2025-06-20",{"date":72,"type":21},"2027-06-30",{"name":74,"class":41},"Radboud University Medical Center"]